-
市场
-
产品
-
资讯
-
Moo社区
-
课堂
-
查看更多
-
功能介绍
-
费用费用透明,无最低余额限制
投资选择、功能介绍、费用相关信息由Moomoo Financial Inc.提供
- English
- 中文繁體
- 中文简体
- 深色
- 浅色
Clover Biopharmaceuticals, Ltd.'s (HKG:2197) Market Cap Surged HK$2.7b Last Week, Individual Investors Who Have a Lot Riding on the Company Were Rewarded
Clover Biopharmaceuticals, Ltd.'s (HKG:2197) Market Cap Surged HK$2.7b Last Week, Individual Investors Who Have a Lot Riding on the Company Were Rewarded
Every investor in Clover Biopharmaceuticals, Ltd. (HKG:2197) should be aware of the most powerful shareholder groups. And the group that holds the biggest piece of the pie are individual investors with 29% ownership. Put another way, the group faces the maximum upside potential (or downside risk).
Clearly, individual investors benefitted the most after the company's market cap rose by HK$2.7b last week.
In the chart below, we zoom in on the different ownership groups of Clover Biopharmaceuticals.
View our latest analysis for Clover Biopharmaceuticals
SEHK:2197 Ownership Breakdown November 20th 2022What Does The Institutional Ownership Tell Us About Clover Biopharmaceuticals?
Many institutions measure their performance against an index that approximates the local market. So they usually pay more attention to companies that are included in major indices.
As you can see, institutional investors have a fair amount of stake in Clover Biopharmaceuticals. This implies the analysts working for those institutions have looked at the stock and they like it. But just like anyone else, they could be wrong. When multiple institutions own a stock, there's always a risk that they are in a 'crowded trade'. When such a trade goes wrong, multiple parties may compete to sell stock fast. This risk is higher in a company without a history of growth. You can see Clover Biopharmaceuticals' historic earnings and revenue below, but keep in mind there's always more to the story.
SEHK:2197 Earnings and Revenue Growth November 20th 2022Clover Biopharmaceuticals is not owned by hedge funds. Because actions speak louder than words, we consider it a good sign when insiders own a significant stake in a company. In Clover Biopharmaceuticals' case, its Top Key Executive, Peng Liang, is the largest shareholder, holding 18% of shares outstanding. In comparison, the second and third largest shareholders hold about 15% and 7.8% of the stock. In addition, we found that Joshua G. Liang, the CEO has 1.6% of the shares allocated to their name.
On looking further, we found that 51% of the shares are owned by the top 5 shareholders. In other words, these shareholders have a meaningful say in the decisions of the company.
Researching institutional ownership is a good way to gauge and filter a stock's expected performance. The same can be achieved by studying analyst sentiments. There is a little analyst coverage of the stock, but not much. So there is room for it to gain more coverage.
Insider Ownership Of Clover Biopharmaceuticals
The definition of an insider can differ slightly between different countries, but members of the board of directors always count. Company management run the business, but the CEO will answer to the board, even if he or she is a member of it.
Insider ownership is positive when it signals leadership are thinking like the true owners of the company. However, high insider ownership can also give immense power to a small group within the company. This can be negative in some circumstances.
It seems insiders own a significant proportion of Clover Biopharmaceuticals, Ltd.. It has a market capitalization of just HK$6.0b, and insiders have HK$1.3b worth of shares in their own names. We would say this shows alignment with shareholders, but it is worth noting that the company is still quite small; some insiders may have founded the business. You can click here to see if those insiders have been buying or selling.
General Public Ownership
The general public-- including retail investors -- own 29% stake in the company, and hence can't easily be ignored. While this size of ownership may not be enough to sway a policy decision in their favour, they can still make a collective impact on company policies.
Private Equity Ownership
With a stake of 23%, private equity firms could influence the Clover Biopharmaceuticals board. Some might like this, because private equity are sometimes activists who hold management accountable. But other times, private equity is selling out, having taking the company public.
Private Company Ownership
Our data indicates that Private Companies hold 6.1%, of the company's shares. Private companies may be related parties. Sometimes insiders have an interest in a public company through a holding in a private company, rather than in their own capacity as an individual. While it's hard to draw any broad stroke conclusions, it is worth noting as an area for further research.
Next Steps:
It's always worth thinking about the different groups who own shares in a company. But to understand Clover Biopharmaceuticals better, we need to consider many other factors. Be aware that Clover Biopharmaceuticals is showing 2 warning signs in our investment analysis , you should know about...
Ultimately the future is most important. You can access this free report on analyst forecasts for the company.
NB: Figures in this article are calculated using data from the last twelve months, which refer to the 12-month period ending on the last date of the month the financial statement is dated. This may not be consistent with full year annual report figures.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
每一位三叶草生物制药有限公司(HKG:2197)的投资者都应该知道最强大的股东群体。而持有这块蛋糕最大份额的群体是拥有29%股权的个人投资者。换句话说,该集团面临着最大的上行潜力(或下行风险)。
显然,在上周该公司市值上涨27亿港元后,散户投资者受益最大。
在下面的图表中,我们放大了三叶草生物制药的不同所有权组。
查看我们对三叶草生物制药的最新分析
联交所:2197拥有权分类2022年11月20日关于三叶草生物制药公司,机构所有权告诉了我们什么?
许多机构以一个接近当地市场的指数来衡量它们的表现。因此,他们通常更关注那些被纳入主要指数的公司。
正如你所看到的,机构投资者在三叶草生物制药公司持有相当数量的股份。这意味着为这些机构工作的分析师已经看过了这只股票,他们喜欢它。但就像其他人一样,他们也可能错了。当多家机构持有一只股票时,它们总是面临“拥挤交易”的风险。当这样的交易出错时,多方可能会竞相快速抛售股票。在一家没有增长历史的公司,这一风险更高。你可以在下面看到三叶草生物制药公司的历史收益和收入,但请记住,故事总是有更多的内容。
联交所:2197盈利及收入增长2022年11月20日三叶草生物制药公司并非由对冲基金所有。由于行动胜于雄辩,我们认为,当内部人士持有一家公司的大量股份时,这是一个好迹象。在三叶草生物制药公司的案例中,其最高高管彭亮是最大股东,持有18%的流通股。相比之下,第二大股东和第三大股东分别持有约15%和7.8%的股份。此外,我们发现,首席执行官梁朝伟有1.6%的股份分配给他们的名字。
进一步观察,我们发现前五大股东持有51%的股份。换句话说,这些股东在公司的决策中拥有有意义的发言权。
研究机构持股是衡量和筛选股票预期表现的好方法。通过研究分析师的情绪,也可以达到同样的效果。分析师对该股的报道不多,但也不多。因此,它有获得更多报道的空间。
三叶草生物制药的内部人所有权
不同国家对内部人的定义可能略有不同,但董事会成员总是算数的。公司管理层管理企业,但首席执行官将向董事会负责,即使他或她是董事会成员。
内部人持股是积极的,当它标志着领导层像公司的真正所有者一样思考时。然而,高内部人持股也可以给公司内部的一个小团体带来巨大的权力。在某些情况下,这可能是负面的。
内部人士似乎拥有三叶草生物制药有限公司相当大的比例。它的市值只有60亿港元,内部人士以自己的名义持有价值13亿港元的股票。我们会说,这表明了与股东的一致,但值得注意的是,该公司仍相当小;一些内部人士可能创建了这家企业。你可以点击这里,看看这些内部人士是一直在买入还是卖出。
一般公有制
包括散户投资者在内的普通公众持有该公司29%的股份,因此不能轻易忽视。尽管这种规模的所有权可能不足以影响有利于他们的政策决定,但他们仍然可以对公司政策产生集体影响。
私募股权所有权
私募股权公司持有23%的股份,可能会影响克洛弗生物制药公司的董事会。一些人可能会喜欢这样,因为私人股本有时是让管理层承担责任的积极分子。但在其他时候,私募股权公司让公司上市后,它们的股票都卖光了。
私营公司所有权
我们的数据显示,私营公司持有该公司6.1%的股份。私营公司可能是关联方。有时,内部人士通过持有一家私人公司来对上市公司感兴趣,而不是以个人身份。虽然很难得出任何大致的中风结论,但值得注意的是,这是一个值得进一步研究的领域。
接下来的步骤:
拥有一家公司股票的不同集团总是值得考虑的。但为了更好地了解三叶草生物制药公司,我们需要考虑许多其他因素。请注意,三叶草生物制药公司正在展示我们的投资分析中的2个警告信号,你应该知道关于……
最终未来是最重要的。您可以访问此免费分析师对该公司的预测报告。
注:本文中的数字是使用过去12个月的数据计算的,指的是截至财务报表日期的最后一个月的12个月期间。这可能与全年的年度报告数字不一致。
对这篇文章有什么反馈吗?担心内容吗? 保持联系直接与我们联系。或者,也可以给编辑组发电子邮件,地址是implywallst.com。
本文由Simply Wall St.撰写,具有概括性。我们仅使用不偏不倚的方法提供基于历史数据和分析师预测的评论,我们的文章并不打算作为财务建议。它不构成买卖任何股票的建议,也没有考虑你的目标或你的财务状况。我们的目标是为您带来由基本面数据驱动的长期重点分析。请注意,我们的分析可能不会将最新的对价格敏感的公司公告或定性材料考虑在内。Simply Wall St.对上述任何一只股票都没有持仓。
moomoo是Moomoo Technologies Inc.公司提供的金融信息和交易应用程序。
在美国,moomoo上的投资产品和服务由Moomoo Financial Inc.提供,一家受美国证券交易委员会(SEC)监管的持牌主体。 Moomoo Financial Inc.是金融业监管局(FINRA)和证券投资者保护公司(SIPC)的成员。
在新加坡,moomoo上的投资产品和服务是通过Moomoo Financial Singapore Pte. Ltd.提供,该公司受新加坡金融管理局(MAS)监管(牌照号码︰CMS101000) ,持有资本市场服务牌照 (CMS) ,持有财务顾问豁免(Exempt Financial Adviser)资质。本内容未经新加坡金融管理局的审查。
在澳大利亚,moomoo上的金融产品和服务是通过Futu Securities (Australia) Ltd提供,该公司是受澳大利亚证券和投资委员会(ASIC)监管的澳大利亚金融服务许可机构(AFSL No. 224663)。请阅读并理解我们的《金融服务指南》、《条款与条件》、《隐私政策》和其他披露文件,这些文件可在我们的网站 https://www.moomoo.com/au中获取。
在加拿大,通过moomoo应用提供的仅限订单执行的券商服务由Moomoo Financial Canada Inc.提供,并受加拿大投资监管机构(CIRO)监管。
在马来西亚,moomoo上的投资产品和服务是通过Moomoo Securities Malaysia Sdn. Bhd. 提供,该公司受马来西亚证券监督委员会(SC)监管(牌照号码︰eCMSL/A0397/2024) ,持有资本市场服务牌照 (CMSL) 。本内容未经马来西亚证券监督委员会的审查。
Moomoo Technologies Inc., Moomoo Financial Inc., Moomoo Financial Singapore Pte. Ltd., Futu Securities (Australia) Ltd, Moomoo Financial Canada Inc.,和Moomoo Securities Malaysia Sdn. Bhd.是关联公司。
风险及免责提示
moomoo是Moomoo Technologies Inc.公司提供的金融信息和交易应用程序。
在美国,moomoo上的投资产品和服务由Moomoo Financial Inc.提供,一家受美国证券交易委员会(SEC)监管的持牌主体。 Moomoo Financial Inc.是金融业监管局(FINRA)和证券投资者保护公司(SIPC)的成员。
在新加坡,moomoo上的投资产品和服务是通过Moomoo Financial Singapore Pte. Ltd.提供,该公司受新加坡金融管理局(MAS)监管(牌照号码︰CMS101000) ,持有资本市场服务牌照 (CMS) ,持有财务顾问豁免(Exempt Financial Adviser)资质。本内容未经新加坡金融管理局的审查。
在澳大利亚,moomoo上的金融产品和服务是通过Futu Securities (Australia) Ltd提供,该公司是受澳大利亚证券和投资委员会(ASIC)监管的澳大利亚金融服务许可机构(AFSL No. 224663)。请阅读并理解我们的《金融服务指南》、《条款与条件》、《隐私政策》和其他披露文件,这些文件可在我们的网站 https://www.moomoo.com/au中获取。
在加拿大,通过moomoo应用提供的仅限订单执行的券商服务由Moomoo Financial Canada Inc.提供,并受加拿大投资监管机构(CIRO)监管。
在马来西亚,moomoo上的投资产品和服务是通过Moomoo Securities Malaysia Sdn. Bhd. 提供,该公司受马来西亚证券监督委员会(SC)监管(牌照号码︰eCMSL/A0397/2024) ,持有资本市场服务牌照 (CMSL) 。本内容未经马来西亚证券监督委员会的审查。
Moomoo Technologies Inc., Moomoo Financial Inc., Moomoo Financial Singapore Pte. Ltd., Futu Securities (Australia) Ltd, Moomoo Financial Canada Inc.,和Moomoo Securities Malaysia Sdn. Bhd.是关联公司。
- 分享到weixin
- 分享到qq
- 分享到facebook
- 分享到twitter
- 分享到微博
- 粘贴板
使用浏览器的分享功能,分享给你的好友吧